PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, К. К. Лактионов, Alexey E. Vasiliev, Dmytro Trukhin, Sujeong Kim, G. Ursol, Maen Hussein, F. Lim, Chun Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Xiaoshun Shi, L. Poole, Solange Peters, Edward B. Garon, Tony Mok